Table 3.
Selected follow‐up clinicopathologic data (median; interquartile range) in 262 131I‐treated hyperthyroid cats, divided into 2 groups based on serum creatinine concentration: Pre‐azotemic cats, which have developed azotemic chronic kidney disease after 131I treatment (n = 42), and nonazotemic cats, which maintained normal serum creatinine concentrations after 131I treatment (n = 220)
| Variable | Pre‐azotemic (42) | Nonazotemic (220) | P Value |
|---|---|---|---|
| Age (years) | 14 (12–15) | 12 (10–13) | <0.001 |
| Body weight (kg) | 4.6 (3.8–5.5) | 4.9 (4.2–6.1) | 0.050 |
| Muscle wasting (%) | 24 (57.1) | 83 (37.7) | 0.025 |
| Serum urea nitrogen (mg/dL) | 44 (37–48) | 29 (24–34) | <0.001 |
| Serum creatinine (mg/dL) | 2.5 (2.4–2.9) | 1.5 (1.3–1.8) | <0.001 |
| Serum symmetric dimethylarginine (μg/dL) | 18 (16–22) | 11 (9–13) | <0.001 |
| Serum T4 (μg/dL) | 1.6 (1.2–2.1) | 1.9 (1.5–2.2) | 0.007 |
| Serum thyroid‐stimulating hormone (ng/mL) | 0.27 (0.08–0.89) | 0.10 (0.02–0.24) | <0.001 |
| Recheck time (months) | 6 (5–7) | 6 (6–7) | 0.16 |